Activating RNA, mastering disease.

ABOUT MiNA

Harnessing innate mechanisms of gene activation, small activating RNA (RNAa) therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes in patients’ cells. We are advancing a proprietary pipeline of new medicines with an initial focus on genetic medicine, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of other therapeutic areas.

NEW CLASS OF MEDICINES

Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.

CLINICAL STAGE PLATFORM

We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.

EXPERIENCED TEAM

Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, oncology and immunology.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close